Recordati Group

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Recordati Group sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 3 currently recruiting 4 completed early-phase tilt top decile by trial count

Recordati Group: 11 sponsored US clinical trials, 3 recruiting.

Recordati Group sponsors 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Endogenous Cushing's Syndrome, with 1 trials.

Top-decile sponsor footprint

Recordati Group ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

NCT05040178
RECRUITING Phase 2

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT03708900
RECRUITING

Cold Agglutinin Disease Real World Evidence Registry

NCT05791708
ACTIVE NOT RECRUITING Phase 2

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

NCT05928390
ACTIVE NOT RECRUITING

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156
TERMINATED Phase 2

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

NCT04838860
TERMINATED Phase 3

SILtuximab in Viral ARds (SILVAR) Study

NCT04616586
COMPLETED Phase 2

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
COMPLETED Phase 2

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

NCT03606408
COMPLETED Phase 4

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
COMPLETED

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

NCT02310269

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 1
Phase 4 1

Therapeutic Areas

Endogenous Cushing's Syndrome 1
Cold Agglutinin Syndrome (CAS) 1
Cold Agglutinin Disease (CAD) 1
Post-Bariatric Hypoglycemia 1
Cushing Syndrome 1
Hyperammonemia 1
Propionic Acidemia 1
Methylmalonic Acidemia 1

What is open in the Recordati Group pipeline

3 recruiting of 11 indexed (27% open); 4 completed (36%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Endogenous Cushing's Syndrome (1 trial), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Recordati Group: open-pipeline peers nationwide

Peers matched on 11 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

Recordati Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share Recordati GroupAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeConnecticut Children's Medical CenterCriteriumMinneapolis Heart Institute FoundationNerviano Medical Sciences
Recordati Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Recordati Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Recordati Group page

11 registered trials is a research-attention snapshot, not an endorsement of Recordati Group or any single study.

  • 3 of Recordati Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Endogenous Cushing's Syndrome is the condition Recordati Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Endogenous Cushing's Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Recordati Group pipeline card: 11 registered trials from official public datasets.Report a data error.